Wall Street analyst estimates for Cigna Corporation (CI): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions.
Consensus price target
$342.08 (+16% vs price $295.44)
between $302.00 and $400.00 · 7 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $287B | $283B – $291B | $30.51 | 15 |
| 2027E | $300B | $294B – $308B | $33.49 | 15 |
| 2028E | $316B | $306B – $324B | $37.14 | 12 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 28 |
| Hold | 11 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 39 |
| Avg rating (−2 sell to +2 buy) | 0.72 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $7.52 | ||
| 2026-07-30 | $7.78 | $7.60 | +2.4% |
| 2026-04-30 | $7.79 | $7.60 | +2.5% |
| 2026-02-05 | $8.08 | $7.88 | +2.5% |
| 2025-10-30 | $7.83 | $7.64 | +2.5% |
| 2025-07-31 | $7.20 | $7.16 | +0.6% |
| 2025-05-02 | $6.74 | $6.35 | +6.1% |
| 2025-01-30 | $6.64 | $7.84 | -15.3% |
Valuation Ratios
| P/E Ratio | 12.23 |
| Price / Book | 1.83 |
| Dividend Yield | 2.10% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.84B | $41.81B | $48.65B | $153.57B | $160.40B | $174.07B | $180.52B | $195.26B | $247.12B | $274.95B |
| Cost of Revenue | $26.81B | $27.72B | $32.32B | $128.49B | $136.19B | $151.12B | $157.02B | $170.09B | $221.16B | $248.97B |
| Gross Profit | $13.03B | $14.09B | $16.33B | $25.08B | $24.21B | $22.95B | $23.50B | $25.18B | $25.96B | $25.99B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $9.63B | $9.85B | $11.23B | $13.31B | $13.66B | $12.79B | $13.04B | $14.32B | $14.57B | $14.00B |
| Operating Expenses | $9.94B | $10.14B | $12.17B | $17.00B | $16.05B | $15.01B | $15.05B | $16.64B | $16.55B | $16.86B |
| Operating Income | $3.09B | $3.94B | $4.16B | $8.08B | $8.15B | $7.94B | $8.45B | $8.54B | $9.42B | $9.13B |
| EBITDA | $3.86B | $4.69B | $5.56B | $12.47B | $11.37B | $11.09B | $11.52B | $12.07B | $12.47B | $11.75B |
| Interest Expense | $278.0M | $252.0M | $498.0M | $1.68B | $1.44B | $1.21B | $1.23B | $1.45B | $1.44B | $1.38B |
| Pre-tax Income | $2.98B | $3.61B | $3.58B | $6.57B | $10.87B | $6.79B | $8.40B | $5.51B | $5.27B | $7.59B |
| Income Tax | $1.14B | $1.37B | $935.0M | $1.45B | $2.38B | $1.37B | $1.61B | $141.0M | $1.49B | $1.34B |
| Net Income | $1.87B | $2.24B | $2.64B | $5.10B | $8.46B | $5.37B | $6.70B | $5.16B | $3.43B | $5.96B |
| EPS | $7.31 | $9.17 | $10.69 | $13.58 | $23.17 | $15.89 | $21.66 | $17.57 | $12.25 | $22.30 |
| EPS (Diluted) | $7.19 | $9.17 | $10.54 | $13.44 | $22.96 | $15.75 | $21.41 | $17.39 | $12.12 | $22.17 |
| Shares Outstanding (Diluted) | 259.6 M | 244.0 M | 246.7 M | 379.8 M | 368.4 M | 341.0 M | 313.1 M | 296.9 M | 283.2 M | 265.9 M |
Price
| Price | $295.44 (closing price, November 3, 2026) |
| Market Cap | $78.1B |
| Exchange | NYSE |
| Country | US |
Related companies: UNH · CVS · ELV · HUM · CNC · MOH · OSCR
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of CI: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks